text
stringlengths 81
4.38k
|
|---|
<s>[INST] Provide exclusion criteria for trial id: NCT01299623 [/INST] Non-African American
Male
Under 35 or over 70 years of age
Personal history of cancer
Not a resident of Philadelphia Metropolitan Area </s> |
<s>[INST] Provide description for trial id: NCT01299623 [/INST] We will develop and evaluate a community-based approach for disseminating comparative effective reviews (CERs) about breast cancer prevention to African American women. The specific aims of our research, as shown below, will target this population because of persistent disparities in breast cancer morbidity and mortality among this population. Our primary aims are:
To evaluate uptake of a community-based strategy for disseminating CERs about breast cancer prevention to African American women based on sociodemographic characteristics, beliefs about medical research, and medical history. We predict that participation in a community forum will be higher among women with greater socioeconomic resources, those who have a family history of breast cancer, and women who have more positive beliefs about research.
To evaluate the impact of evidential versus non-evidential content about breast cancer prevention on psychological and behavioral outcomes that include: knowledge of breast cancer risk factors and prevention strategies, communication with individuals in their social and medical network, and distrust of medical research. We predict that women who receive evidential content that is specific for African American women will report greater knowledge about breast cancer risk factors and prevention strategies, will be more likely to discuss breast cancer prevention strategies with individuals in their social and medical network, and will report greater reductions in distrust of medical research compared to those who receive non-evidential content. </s> |
<s>[INST] Provide title for trial id: NCT01299623 [/INST] Breast Cancer Prevention Education </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01299623 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT01299623 [/INST] Breast Cancer Prevention </s> |
<s>Trial Id: Ethnic Predisposition, Risk Factors & Breast Cancer Presentation. Recruitment Status: Completed Trail description: Breast cancer, a leading cause of mortality among females, has been the center of research for many decades. Work is in progress to further advance the research worldwide and in our region. This study is conducted to look into regional ethical predilection, clinical presentation/stage, pathological subtypes & risk factors of BC among patients of Karachi, with the aim of proposing a ground to policy making regarding protocol setting for screening and management of BC for our region. Inclusion Criteria: female sex, age ≥ 20 years, patients with availability of complete clinical details, biopsy proven breast cancer, no previous history of breast cancer treatment from other centers, males, all regional ethnicities(residents of Karachi, Sindh) and all stages of breast cancer Exclusion Criteria: previously treated breast cancer patients, female ≤19 years, male/transgender, females coming for treatment for other provinces/foreigners. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT05458570 [/INST] female sex, age ≥ 20 years, patients with availability of complete clinical details, biopsy proven breast cancer, no previous history of breast cancer treatment from other centers, males, all regional ethnicities(residents of Karachi, Sindh) and all stages of breast cancer </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT05458570 [/INST] previously treated breast cancer patients, female ≤19 years, male/transgender, females coming for treatment for other provinces/foreigners. </s> |
<s>[INST] Provide description for trial id: NCT05458570 [/INST] Breast cancer, a leading cause of mortality among females, has been the center of research for many decades. Work is in progress to further advance the research worldwide and in our region. This study is conducted to look into regional ethical predilection, clinical presentation/stage, pathological subtypes & risk factors of BC among patients of Karachi, with the aim of proposing a ground to policy making regarding protocol setting for screening and management of BC for our region. </s> |
<s>[INST] Provide title for trial id: NCT05458570 [/INST] Ethnic Predisposition, Risk Factors & Breast Cancer Presentation. </s> |
<s>[INST] Provide the recruitment status for trial id: NCT05458570 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT05458570 [/INST] Breast Cancer </s> |
<s>Trial Id: Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment Recruitment Status: Unknown status Trail description: Breast cancer directly affects women physically, psychologically and socially in the process of diagnosis, treatment and post-treatment. Despite the improvement in conventional breast cancer treatments that led to longer disease-free survival, many patients still suffer from physical, psychological, social and spiritual problems after treatment. The neglect of physical and psychosocial problems faced by patients who are between 1 and 2 years after the end of treatment negatively impacts the quality of life of this population. Inclusion Criteria: Breast cancer
Adult women (age ≥ 20 years old and less than 60 years old)
Patient who has been treated by surgery, with or without adjuvant chemotherapy
Clinical Stages I, II and III
Patients considered cured, without history of recurrences
Patients who completed treatment within a minimum of 1 year and are currently being undergoing outpatient follow-up Exclusion Criteria: Initial diagnosis of another type of cancer, other than breast cancer
Bilateral breast cancer
Patient unable to fill out the QoL questionnaire
Patient with disease recurrence
Patient with metastatic breast cancer </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04834570 [/INST] Breast cancer
Adult women (age ≥ 20 years old and less than 60 years old)
Patient who has been treated by surgery, with or without adjuvant chemotherapy
Clinical Stages I, II and III
Patients considered cured, without history of recurrences
Patients who completed treatment within a minimum of 1 year and are currently being undergoing outpatient follow-up </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04834570 [/INST] Initial diagnosis of another type of cancer, other than breast cancer
Bilateral breast cancer
Patient unable to fill out the QoL questionnaire
Patient with disease recurrence
Patient with metastatic breast cancer </s> |
<s>[INST] Provide description for trial id: NCT04834570 [/INST] Breast cancer directly affects women physically, psychologically and socially in the process of diagnosis, treatment and post-treatment. Despite the improvement in conventional breast cancer treatments that led to longer disease-free survival, many patients still suffer from physical, psychological, social and spiritual problems after treatment. The neglect of physical and psychosocial problems faced by patients who are between 1 and 2 years after the end of treatment negatively impacts the quality of life of this population. </s> |
<s>[INST] Provide title for trial id: NCT04834570 [/INST] Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment </s> |
<s>[INST] Provide the recruitment status for trial id: NCT04834570 [/INST] Unknown status </s> |
<s>[INST] Provide the medical condition for trial id: NCT04834570 [/INST] Breast Cancer </s> |
<s>Trial Id: No Axillary Surgery for Early Breast Cancer. Recruitment Status: Completed Trail description: After breast cancer (BC) screening was introduced for all Swedish women in 1989-90 the number of early invasive BC, clin N0 rose dramatically. For these BC it was known that only 10 % or less was N+ after axillary dissection and the morbidity for axillary surgery was substantial. Omitting axillary dissection in a randomized trial was ruled out because of anticipated few events. A national cohort was decided for invasive unifocal BC, histological grade 1 or 2, T=max 10mm, free margins, clin node neg. No axillary dissection should be undertaken. This was before the Sentinel Node era. Adjuvant treatment could be given according to regional guidelines for early breast cancer. Not uniform concerning postoperative radiotherapy and antihormonal treatment. Follow-up was clinical the first 5 years with mammography and then by hospital records and national Death register. Primary aim: Number of axillary recurrence and BC specific survival. Inclusion Criteria: Invasive breast cancer, unifocal
T=max 10mm
Clinical node negative and clinical M0
Histological grade 1 or 2
Both screening / clinical detected accepted
Radical operation = free margins in breast specimen
Partial mastectomy and mastectomy accepted
Fit to understand inclusion criteria Exclusion Criteria: Previous breast cancer diagnosis, including carcinoma in situ
Previous ipsilateral axillary dissection
Non radical operation = no free margins
Multifocal cancer
Previous treatment for other cancer.
Unable to understand information (informed consent)
Bilateral breast cancer at diagnosis </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT03669705 [/INST] Invasive breast cancer, unifocal
T=max 10mm
Clinical node negative and clinical M0
Histological grade 1 or 2
Both screening / clinical detected accepted
Radical operation = free margins in breast specimen
Partial mastectomy and mastectomy accepted
Fit to understand inclusion criteria </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT03669705 [/INST] Previous breast cancer diagnosis, including carcinoma in situ
Previous ipsilateral axillary dissection
Non radical operation = no free margins
Multifocal cancer
Previous treatment for other cancer.
Unable to understand information (informed consent)
Bilateral breast cancer at diagnosis </s> |
<s>[INST] Provide description for trial id: NCT03669705 [/INST] After breast cancer (BC) screening was introduced for all Swedish women in 1989-90 the number of early invasive BC, clin N0 rose dramatically. For these BC it was known that only 10 % or less was N+ after axillary dissection and the morbidity for axillary surgery was substantial. Omitting axillary dissection in a randomized trial was ruled out because of anticipated few events. A national cohort was decided for invasive unifocal BC, histological grade 1 or 2, T=max 10mm, free margins, clin node neg. No axillary dissection should be undertaken. This was before the Sentinel Node era. Adjuvant treatment could be given according to regional guidelines for early breast cancer. Not uniform concerning postoperative radiotherapy and antihormonal treatment. Follow-up was clinical the first 5 years with mammography and then by hospital records and national Death register. Primary aim: Number of axillary recurrence and BC specific survival. </s> |
<s>[INST] Provide title for trial id: NCT03669705 [/INST] No Axillary Surgery for Early Breast Cancer. </s> |
<s>[INST] Provide the recruitment status for trial id: NCT03669705 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT03669705 [/INST] Breast Cancer Invasive </s> |
<s>Trial Id: Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy Recruitment Status: Recruiting Trail description: This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis. Inclusion Criteria: Age ≥18 years
Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy
LVEF≥53% before chemotherapy Exclusion Criteria: life expectancy ≤12 months
Participating in other ongoing oncology clinical trials
Prior treatment with anthracyclines or chest radiation therapy
Pregnant or lactating women
Ultrasound images of the heart are of very poor quality </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT06282796 [/INST] Age ≥18 years
Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy
LVEF≥53% before chemotherapy </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT06282796 [/INST] life expectancy ≤12 months
Participating in other ongoing oncology clinical trials
Prior treatment with anthracyclines or chest radiation therapy
Pregnant or lactating women
Ultrasound images of the heart are of very poor quality </s> |
<s>[INST] Provide description for trial id: NCT06282796 [/INST] This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis. </s> |
<s>[INST] Provide title for trial id: NCT06282796 [/INST] Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy </s> |
<s>[INST] Provide the recruitment status for trial id: NCT06282796 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT06282796 [/INST] Breast Cancer </s> |
<s>Trial Id: Increasing African Immigrant Women's Participation in Breast Cancer Screening Recruitment Status: Completed Trail description: New York City (NYC) is home to a large and diverse immigrant population. Many of these groups face significant barriers to preventive health care, including lack of insurance, poor health care access and language difficulties. Most African immigrant women are likely to live below the poverty line and have low health literacy, are less likely to have health insurance and visit a doctor, particularly for primary/preventive care. Without access to primary care, many preventive services, such as breast cancer screenings go unattended. The barriers and facilitators to breast cancer screening for other minority groups from underserved populations, such as African Americans and Latina women have been studied. Less is known about these for African immigrant women and how to most effectively engage their participation in regular screening. Data of over 2,000 African-born immigrants living in NYC show that 77% report not having health insurance; 75% do not have a primary care physician; and 57% have less than a high school education. As for cancer screening, when corrected for age, 44% have never had a mammogram. Through the study team's unique collaboration with the African Services Committee and the African Advisory Council of the Bronx, two non-governmental community-based service organizations, the study team is poised to have a significant impact on these immigrant women, who have emigrated from more than 20 countries in Africa. This is a population with great need for increased breast cancer knowledge, access to breast cancer screening, and basic medical care. The Health Belief Model (HBM) provides a framework for addressing cultural health barriers by positing that making a decision to engage in a health behavior is determined by weighing perceived threats versus benefits. The long term goal of the proposed project is to conduct a randomized clinical trial that tests the adapted intervention to increase breast cancer screening rates for African-born immigrants. In the short term, the study team plans to pursue the following specific aims: (1) Identify barriers and facilitators to breast cancer screening among African-born immigrants and (2) Culturally adapt and pilot test the Witness Project breast cancer education program for African-born women. Thus, the study team will culturally adapt an effective, innovative intervention to address this significant health disparity in African-born immigrant communities. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04450264 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04450264 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT04450264 [/INST] New York City (NYC) is home to a large and diverse immigrant population. Many of these groups face significant barriers to preventive health care, including lack of insurance, poor health care access and language difficulties. Most African immigrant women are likely to live below the poverty line and have low health literacy, are less likely to have health insurance and visit a doctor, particularly for primary/preventive care. Without access to primary care, many preventive services, such as breast cancer screenings go unattended. The barriers and facilitators to breast cancer screening for other minority groups from underserved populations, such as African Americans and Latina women have been studied. Less is known about these for African immigrant women and how to most effectively engage their participation in regular screening. Data of over 2,000 African-born immigrants living in NYC show that 77% report not having health insurance; 75% do not have a primary care physician; and 57% have less than a high school education. As for cancer screening, when corrected for age, 44% have never had a mammogram. Through the study team's unique collaboration with the African Services Committee and the African Advisory Council of the Bronx, two non-governmental community-based service organizations, the study team is poised to have a significant impact on these immigrant women, who have emigrated from more than 20 countries in Africa. This is a population with great need for increased breast cancer knowledge, access to breast cancer screening, and basic medical care. The Health Belief Model (HBM) provides a framework for addressing cultural health barriers by positing that making a decision to engage in a health behavior is determined by weighing perceived threats versus benefits. The long term goal of the proposed project is to conduct a randomized clinical trial that tests the adapted intervention to increase breast cancer screening rates for African-born immigrants. In the short term, the study team plans to pursue the following specific aims: (1) Identify barriers and facilitators to breast cancer screening among African-born immigrants and (2) Culturally adapt and pilot test the Witness Project breast cancer education program for African-born women. Thus, the study team will culturally adapt an effective, innovative intervention to address this significant health disparity in African-born immigrant communities. </s> |
<s>[INST] Provide title for trial id: NCT04450264 [/INST] Increasing African Immigrant Women's Participation in Breast Cancer Screening </s> |
<s>[INST] Provide the recruitment status for trial id: NCT04450264 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT04450264 [/INST] Breast Cancer </s> |
<s>Trial Id: A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers Recruitment Status: Completed Trail description: In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure. Inclusion Criteria: Age greater than or equal to 18 years
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ
Patient desire to undergo breast surgery
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted
The cancer enhances on breast MRI imaging. Exclusion Criteria: Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes
Severe claustrophobia
Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)
History of median sternotomy
Pregnancy. Patient attestation that they are not pregnant will be acceptable as per standard policy for MRIs at DHMC. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT02550210 [/INST] Age greater than or equal to 18 years
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ
Patient desire to undergo breast surgery
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted
The cancer enhances on breast MRI imaging. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT02550210 [/INST] Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes
Severe claustrophobia
Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)
History of median sternotomy
Pregnancy. Patient attestation that they are not pregnant will be acceptable as per standard policy for MRIs at DHMC. </s> |
<s>[INST] Provide description for trial id: NCT02550210 [/INST] In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure. </s> |
<s>[INST] Provide title for trial id: NCT02550210 [/INST] A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers </s> |
<s>[INST] Provide the recruitment status for trial id: NCT02550210 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT02550210 [/INST] Breast Cancer </s> |
<s>Trial Id: The HIFUB Study (HIFU in Breast Cancer) Recruitment Status: Unknown status Trail description: High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.
In this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated Inclusion Criteria: Participant is willing and able to give informed consent for participation in the trial.
Female, aged 18 years or above.
Histologically confirmed breast cancer (invasive ductal cancer) by core biopsy, which is suitable for surgical resection.
Participants must have one non-metastatic, clinically palpable, invasive breast cancer measuring ≤2cm in its largest dimension, which can be visualised using diagnostic ultrasound.
All participants must have an adequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Adequate ECG, haematological, renal and hepatic function, as indicated, as would be required for imaging and surgery.
In the Investigator's opinion, is able and willing to comply with all trial requirements. Exclusion Criteria: Female participant who is pregnant.
Significant renal or hepatic impairment.
An inadequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Unable to visualize lesion or tumour boundaries clearly on ultrasound.
Subjects with tumours lying less than 5mm to overlying skin or less than 5mm to the underlying muscle on the diagnostic scan.
Any uncontrolled illness or any other medical problem that would preclude surgery.
The presence of any contraindication for magnetic resonance imaging, e.g. the presence of a heart pacemaker, a metallic foreign body (metal sliver) in the eye, or an aneurysm clip in the brain or severe claustrophobia. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT05350059 [/INST] Participant is willing and able to give informed consent for participation in the trial.
Female, aged 18 years or above.
Histologically confirmed breast cancer (invasive ductal cancer) by core biopsy, which is suitable for surgical resection.
Participants must have one non-metastatic, clinically palpable, invasive breast cancer measuring ≤2cm in its largest dimension, which can be visualised using diagnostic ultrasound.
All participants must have an adequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Adequate ECG, haematological, renal and hepatic function, as indicated, as would be required for imaging and surgery.
In the Investigator's opinion, is able and willing to comply with all trial requirements. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT05350059 [/INST] Female participant who is pregnant.
Significant renal or hepatic impairment.
An inadequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Unable to visualize lesion or tumour boundaries clearly on ultrasound.
Subjects with tumours lying less than 5mm to overlying skin or less than 5mm to the underlying muscle on the diagnostic scan.
Any uncontrolled illness or any other medical problem that would preclude surgery.
The presence of any contraindication for magnetic resonance imaging, e.g. the presence of a heart pacemaker, a metallic foreign body (metal sliver) in the eye, or an aneurysm clip in the brain or severe claustrophobia. </s> |
<s>[INST] Provide description for trial id: NCT05350059 [/INST] High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.
In this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated </s> |
<s>[INST] Provide title for trial id: NCT05350059 [/INST] The HIFUB Study (HIFU in Breast Cancer) </s> |
<s>[INST] Provide the recruitment status for trial id: NCT05350059 [/INST] Unknown status </s> |
<s>[INST] Provide the medical condition for trial id: NCT05350059 [/INST] Breast Cancer </s> |
<s>Trial Id: A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers Recruitment Status: Completed Trail description: The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer. Inclusion Criteria: Age > 18 years.
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
The cancer enhances on prone breast MRI imaging
The cancer is visible on mammography. Exclusion Criteria: Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
Severe claustrophobia.
Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).
History of median sternotomy.
Pregnancy. Patient attestation that they are not pregnant will be acceptable.
Patients receiving neoadjuvant chemotherapy. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT03573661 [/INST] Age > 18 years.
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
The cancer enhances on prone breast MRI imaging
The cancer is visible on mammography. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT03573661 [/INST] Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
Severe claustrophobia.
Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).
History of median sternotomy.
Pregnancy. Patient attestation that they are not pregnant will be acceptable.
Patients receiving neoadjuvant chemotherapy. </s> |
<s>[INST] Provide description for trial id: NCT03573661 [/INST] The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer. </s> |
<s>[INST] Provide title for trial id: NCT03573661 [/INST] A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers </s> |
<s>[INST] Provide the recruitment status for trial id: NCT03573661 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT03573661 [/INST] Palpable Breast Cancer </s> |
<s>Trial Id: Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer Recruitment Status: Not yet recruiting Trail description: Measurement of serum levels of Retinoic acid induced 14 (RAI14) and Metastasis associated cancer colon -1 (MACC-1) as biomarkers for diagnosis of breast cancer.
Study their relationship to disease stages and clinicopathological features of BC.
Compare the diagnostic performance of serum RAI14 and serum MACC-1 with serum Carcinoembryonic antigen (CEA) and Cancer antigen 15-3 (CA15-3) for diagnosis of BC. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT06097546 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT06097546 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT06097546 [/INST] Measurement of serum levels of Retinoic acid induced 14 (RAI14) and Metastasis associated cancer colon -1 (MACC-1) as biomarkers for diagnosis of breast cancer.
Study their relationship to disease stages and clinicopathological features of BC.
Compare the diagnostic performance of serum RAI14 and serum MACC-1 with serum Carcinoembryonic antigen (CEA) and Cancer antigen 15-3 (CA15-3) for diagnosis of BC. </s> |
<s>[INST] Provide title for trial id: NCT06097546 [/INST] Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT06097546 [/INST] Not yet recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT06097546 [/INST] Breast Cancer </s> |
<s>Trial Id: Whole Genome Sequencing in Breast Cancer Recruitment Status: Recruiting Trail description: This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030. Inclusion Criteria: Patients who have consented to both the patient consent form and the consent for the use of human-derived materials.
Patients who are aged 19 years or older at the time of signing the consent form.
Patients capable of providing written consent to participate voluntarily in the study.
Patients eligible for tissue examination and surgical removal to facilitate sample collection.
Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer. Exclusion Criteria: Patients who do not understand or refuse to consent in writing.
Patients for whom obtaining sufficient samples is challenging.
Patients who refuse genetic testing.
[Retrospective study]
Inclusion Criteria:
Patients histologically confirmed with breast cancer.
Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution.
Exclusion Criteria:
- Patients for whom sufficient tissue for analysis is not adequately stored. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT06334471 [/INST] Patients who have consented to both the patient consent form and the consent for the use of human-derived materials.
Patients who are aged 19 years or older at the time of signing the consent form.
Patients capable of providing written consent to participate voluntarily in the study.
Patients eligible for tissue examination and surgical removal to facilitate sample collection.
Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT06334471 [/INST] Patients who do not understand or refuse to consent in writing.
Patients for whom obtaining sufficient samples is challenging.
Patients who refuse genetic testing.
[Retrospective study]
Inclusion Criteria:
Patients histologically confirmed with breast cancer.
Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution.
Exclusion Criteria:
- Patients for whom sufficient tissue for analysis is not adequately stored. </s> |
<s>[INST] Provide description for trial id: NCT06334471 [/INST] This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030. </s> |
<s>[INST] Provide title for trial id: NCT06334471 [/INST] Whole Genome Sequencing in Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT06334471 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT06334471 [/INST] Breast Cancer </s> |
<s>Trial Id: Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer Recruitment Status: Completed Trail description: Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT).
Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters [Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT06212908 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT06212908 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT06212908 [/INST] Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT).
Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters [Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks. </s> |
<s>[INST] Provide title for trial id: NCT06212908 [/INST] Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT06212908 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT06212908 [/INST] Breast Cancer, Gingivitis, Periodontal </s> |
<s>Trial Id: Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology Recruitment Status: Completed Trail description: The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to an extensive intraoperative frozen section protocol for Sentinel Lymph Nodes removed during standard Sentinel Lymph Node biopsy procedures from breast cancer subjects. Inclusion Criteria: Male or female;
18 years of age or older;
Diagnosed pre-surgically with T1 or T2 breast cancer without clinical evidence of axillary lymph node involvement and scheduled for surgery including sentinel lymph node dissection;
Subjects (or the subjects' legal representatives) who have read, understood to the best of their ability and signed the informed consent form. Exclusion Criteria: Subjects diagnosed pre-surgically with large or locally advanced (T3 & T4) breast cancer;
Pregnant subjects, confirmed by interview with either subject or treating physician;
Subjects diagnosed with inflammatory breast cancer;
Subjects diagnosed with ductal carcinoma in situ (DCIS) when breast conservation is to be done;
Subjects with clinically suspicious, palpable axillary lymph nodes;
Subjects previously treated for or previously diagnosed with another type of invasive cancer. Subjects with skin cancer (basal cell and squamous cell carcinoma) may be included, except for subjects diagnosed with melanoma; Subjects with non-invasive carcinoma of the Cervix may also be included in this study.
Subjects who have received pre-operative systemic therapy;
Subjects who are incapable of providing written informed consent;
Subjects who have been judged to be an inappropriate candidate by any medical care provider (e.g., surgeon, oncologist or pathologist).
Subjects participating in other clinical studies where the SLN evaluation will be negatively impacted by this study. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01368744 [/INST] Male or female;
18 years of age or older;
Diagnosed pre-surgically with T1 or T2 breast cancer without clinical evidence of axillary lymph node involvement and scheduled for surgery including sentinel lymph node dissection;
Subjects (or the subjects' legal representatives) who have read, understood to the best of their ability and signed the informed consent form. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01368744 [/INST] Subjects diagnosed pre-surgically with large or locally advanced (T3 & T4) breast cancer;
Pregnant subjects, confirmed by interview with either subject or treating physician;
Subjects diagnosed with inflammatory breast cancer;
Subjects diagnosed with ductal carcinoma in situ (DCIS) when breast conservation is to be done;
Subjects with clinically suspicious, palpable axillary lymph nodes;
Subjects previously treated for or previously diagnosed with another type of invasive cancer. Subjects with skin cancer (basal cell and squamous cell carcinoma) may be included, except for subjects diagnosed with melanoma; Subjects with non-invasive carcinoma of the Cervix may also be included in this study.
Subjects who have received pre-operative systemic therapy;
Subjects who are incapable of providing written informed consent;
Subjects who have been judged to be an inappropriate candidate by any medical care provider (e.g., surgeon, oncologist or pathologist).
Subjects participating in other clinical studies where the SLN evaluation will be negatively impacted by this study. </s> |
<s>[INST] Provide description for trial id: NCT01368744 [/INST] The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to an extensive intraoperative frozen section protocol for Sentinel Lymph Nodes removed during standard Sentinel Lymph Node biopsy procedures from breast cancer subjects. </s> |
<s>[INST] Provide title for trial id: NCT01368744 [/INST] Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01368744 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT01368744 [/INST] Breast Neoplasms, Breast Diseases </s> |
<s>Trial Id: Breast Cancer With Over-expression of erbB2-BRAINSTORM Recruitment Status: Completed Trail description: This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression. Inclusion Criteria: Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only.
Brain metastasis diagnosis made between January 2006 - December 2008. Exclusion Criteria: Women who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis..
Patient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.) </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01064349 [/INST] Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only.
Brain metastasis diagnosis made between January 2006 - December 2008. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01064349 [/INST] Women who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis..
Patient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.) </s> |
<s>[INST] Provide description for trial id: NCT01064349 [/INST] This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression. </s> |
<s>[INST] Provide title for trial id: NCT01064349 [/INST] Breast Cancer With Over-expression of erbB2-BRAINSTORM </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01064349 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT01064349 [/INST] Cancer </s> |
<s>Trial Id: RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients Recruitment Status: Unknown status Trail description: This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy. Inclusion Criteria: Invasive carcinoma of the breast.
Complete microscopic excision of primary tumour and axillary dissection or SLNB .
Females with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy.
Patients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront mastectomy.
Able to comply with follow up.
Written informed consent Exclusion Criteria: Patients do not match with inclusion criteria.
Collagen vascular disease, specifically systemic lupus, or scleroderma.
Pregnancy or lactation at the time of radiotherapy. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04550910 [/INST] Invasive carcinoma of the breast.
Complete microscopic excision of primary tumour and axillary dissection or SLNB .
Females with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy.
Patients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront mastectomy.
Able to comply with follow up.
Written informed consent </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04550910 [/INST] Patients do not match with inclusion criteria.
Collagen vascular disease, specifically systemic lupus, or scleroderma.
Pregnancy or lactation at the time of radiotherapy. </s> |
<s>[INST] Provide description for trial id: NCT04550910 [/INST] This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy. </s> |